PO-1358 Does brachytherapy boost improve biochemical control in intermediate and high-risk prostate cancer?

Miszczyk, Marcin; Jabłońska, Iwona; Krzysztofiak, Tomasz; Magrowski, Łukasz; Majewski, Wojciech; Suwiński, Rafał; Masri, Oliwia; Ciepał, Jakub; Depowska, Gabriela; Gmerek, M.; Nowicka, Elżbieta; Wojcieszek, Piotr

doi:10.1016/s0167-8140(21)07809-9

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The identification of accurate and robust predictive biomarkers associated with prostate cancer patient outcomes following ADT remains an active research hotspot. Since the initial establishment of PSA as a relevant biomarker three decades ago, PSA levels are usually monitored during prostate cancer screening and diagnosis, and also offer value in the context of patient prognostic evaluation (4)(5)(6). After the initiation of ADT in patients with prostate cancer, the PSA levels undergo dynamic changes and monitoring these changes can provide insight into the patient outcomes.…”

Section: Introductionmentioning

confidence: 99%

Dynamic changes in PSA levels predict prognostic outcomes in prostate cancer patients undergoing androgen -deprivation therapy: A multicenter retrospective analysis

Mao²,

Chen³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundAndrogen-deprivation therapy (ADT) is used for the treatment of prostate cancer. However, the specific risk factors for the development of castration-resistant disease are still unclear. The present study sought to identify predictors of patient prognostic outcomes through analyses of clinical findings in large numbers of prostate cancer patients following ADT treatment.MethodsData pertaining to 163 prostate cancer patients treated at the Second Affiliated Hospital of Bengbu Medical University and Maoming People’s Hospital from January 1, 2015, to December 30, 2020, were retrospectively analyzed. Dynamic changes in prostate-specific antigen (PSA) levels were regularly assessed, including both time to nadir (TTN) and nadir PSA (nPSA). Univariate and multivariate analyses were performed with Cox risk proportional regression models, while differences in biochemical progression-free survival (bPFS) were compared among groups with Kaplan-Meier curves and log-rank tests.ResultsThe bPFS values over the median 43.5-month follow-up period differed significantly between patients with nPSA levels < 0.2 ng/mL and ≥ 0.2 ng/mL, being 27.6 months and 13.5 months, respectively (log-rank P < 0.001). A significant difference in median bPFS was also observed when comparing patients with a TTN ≥ 9 months (27.8 months) to those with a TTN < 9 months (13.5 months) (log-rank P < 0.001).ConclusionsTTN and nPSA are valuable predictors of prognosis in prostate cancer patients after ADT treatment, with better outcomes evident in patients with nPSA < 0.2 ng/mL and TTN > 9 months.

show abstract

Section: Introductionmentioning

confidence: 99%